✦ LIBER ✦

7046 Effectiveness of Carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)

✍ Scribed by Reuter, C.W.M.; Morgan, M.A.; Winkler, T.; Fenner, M.; Ganser, A.; Grünwald, V.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7053 POSTER Hormonal Impact of Second-li

✍ Reuter, C.; Morgan, M.; Fenner, M.; Ivanyi, P.; Grünwald, V.; Ganser, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Docetaxel-based chemotherapy as second-l

✍ Shinji Urakami; Tateki Yoshino; Nobuyuki Kikuno; Shin Imai; Satoshi Honda; Tatua 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Cost-Effectiveness Analysis of Abiratero

✍ Shibahara, H.; Shiroiwa, T.; Nakamura, K.; Shimozuma, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Weekly Docetaxel and Bortezomib as First

✍ John D. Hainsworth; Anthony A. Meluch; David R. Spigel; John Barton Jr; Lisa Sim 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 147 KB

305 RESULTS OF A MULTICENTRIC PHASE II R

✍ O. Caffo; E. Comploj; T. Sava; G. Mansueto; F. Zustovich; R. Segati; C. Sacco; A 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 316 KB

P118 Preliminary results of HOPLITE tria

✍ Caffo, O.; Lo Re, G.; Sava, T.; Buti, S.; Sacco, C.; Basso, U.; Zustovich, F.; M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 72 KB